30.08.2012 - Formation of tumours can be significantly reduced by inhibition of a receptor that drives inflammation, according to a British-German research team.
According to the scientists headed by Robert Nibbs from Biomedical Research Centre Glasgow, inhibition of the chemokine receptor CXCR2 „profoundly suppressed inflammation-driven tumourigenesis in models for skin and intestinal cancers as well as in adenomas“ (JCI, doi: 1172/JCI61067). Either chemical blocking of CXCR2 or knock-out of the receptor gene prevented proinflammatory chemokines, which were selectively expressed in adenomas, skin and intestinal tumours, to bind to the receptor. CXCR2 deficiency inhibited recruitment of neutrophils and tumour-associated leukocytes, according to the authors from Glasgow and their partners from Ludwig-Maximilians University Munich.
Chronic inflammation is found frequently in the development of a number of benign and malignant cancers, particularly in colorectal cancers where ulcerative colitis increases the risk of developing colon cancer 20-fold. Treatment of patients with ulcerative colitis with anti-inflammatory compounds can reduce their cancer risk by 50%. Thus, the researchers believe that CRCX2 blockers may be attractive therapeutic targets to prevent and treat inflammation-driven cancers.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.